Dr Kristy Shield-Artin
Honorary (Fellow)
Department of Medical Biology (WEHI)
16 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma
DOI: 10.1186/s13046-025-03629-82025
Journal article
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial
DOI: 10.1038/s41467-025-64130-62024
Journal article
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
DOI: 10.1186/s12943-024-02048-12024
Journal article
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer
DOI: 10.1016/j.isci.2024.1099782023
Journal article
Targeting homologous recombination deficiency in uterine leiomyosarcoma
DOI: 10.1186/s13046-023-02687-02021
Journal article
Oligomerization-driven MLKL ubiquitylation antagonizes necroptosis
DOI: 10.15252/embj.20191037182017
Journal article
Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma
DOI: 10.1158/2159-8290.CD-17-0419
RECENT SCHOLARLY WORKS
2021
Journal article
Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high-grade serous ovarian carcinoma
DOI: 10.1158/0008-5472.CAN-21-07742021
Journal article
Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors
DOI: 10.1038/s41419-020-03269-02020
Journal article
MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis
DOI: 10.1038/s41467-020-16887-12020
Journal article
Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease
DOI: 10.1038/s41586-019-1828-5